New KRAS-Targeting Drug Nearly Doubles Survival in Pancreatic Cancer Trial

A new pancreatic cancer trial has drawn serious attention because the survival gain is unusually large for a disease where progress often comes in small steps.

Daraxonrasib, an oral RAS-targeting drug from Revolution Medicines, helped patients with previously treated metastatic pancreatic ductal adenocarcinoma live a median of 13.2 months, compared with 6.7 months for patients receiving standard chemotherapy.

The company reported a hazard ratio of 0.40, meaning the risk of death was reduced by about 60% in the trial population.

The result matters because pancreatic cancer remains among the hardest major cancers to treat. The National Cancer Institute’s SEER program estimates 67,530 new U.S. cases and 52,740 deaths in 2026. Five-year relative survival across all stages is 13.7%, and only 3.4% for distant disease.

Why The Daraxonrasib Trial Stands Out

Daraxonrasib was tested in the Phase 3 RASolute 302 trial, a global, randomized study in patients with metastatic pancreatic ductal adenocarcinoma who had already received prior treatment.

Patients received either 300 mg of daraxonrasib once daily or an investigator’s choice of standard cytotoxic chemotherapy.

The most important number is overall survival. Progression-free survival also improved, according to Revolution Medicines, and the trial met all primary and key secondary endpoints.

Full peer-reviewed data and detailed subgroup analyses will be important, but the topline finding already sets daraxonrasib apart from many earlier pancreatic cancer studies.

Developments like RASolute 302 are also why many clinicians now follow specialized oncology news closely, since targeted therapy data can change the treatment conversation long before a drug reaches routine clinic use.

What KRAS Has To Do With Pancreatic Cancer

KRAS is one of the main genetic drivers of pancreatic ductal adenocarcinoma. Mutations in RAS proteins, especially KRAS, keep growth signals switched on inside cancer cells.

Pancreatic Cancer Action Network notes that RAS mutations are found in more than 90% of pancreatic adenocarcinoma cases, making the pathway a central target for drug development.

For decades, KRAS was viewed as extremely difficult to drug. The protein’s shape gave researchers few reliable places for a small molecule to attach. Older approaches often tried to block pathways downstream from KRAS, but cancer cells could route around the blockade.

Daraxonrasib belongs to a newer class known as RAS(ON) inhibitors. The drug is designed to interfere with active RAS signaling across several variants, including common G12 mutations such as G12D, G12V, and G12R. That broader approach matters because pancreatic tumors do not all carry the same KRAS variant.

Why a Pill Could Change Daily Treatment

Standard chemotherapy for metastatic pancreatic cancer can be demanding. Regimens often involve infusion visits, fatigue, blood count suppression, nausea, neuropathy, diarrhea, and a heavy schedule for patients already facing advanced disease.

Daraxonrasib is taken orally once daily. That alone does not make a drug easier for every patient, since targeted drugs can still cause serious side effects. Still, a pill can reduce time spent in infusion centers and may give selected patients a different treatment rhythm.

Memorial Sloan Kettering reported that patients in early daraxonrasib studies often had nausea or other gastrointestinal issues at the beginning of treatment, and some developed rash that could require active management.

One patient in an early trial stopped treatment because of side effects. MSK physicians also described a better day-to-day quality of life for many patients compared with chemotherapy.

Side Effects Still Matter

The Phase 3 topline release said daraxonrasib was generally well tolerated, with a manageable safety profile and no new safety signals. That phrasing is encouraging, but it is not the same as saying the drug is easy to take.

PanCAN summarized earlier daraxonrasib experience by noting rash as the most common side effect, with mouth sores, diarrhea, nausea, and vomiting also seen.

Patients and doctors will need full trial tables showing rates of severe toxicity, dose reductions, discontinuations, infections, and quality-of-life outcomes before judging how the survival benefit balances against treatment burden.

For pancreatic cancer, that balance is especially important. Many patients are older, have weight loss, pain, digestive problems, blood clots, diabetes changes, or declining performance status by the time metastatic disease is treated.

A drug that adds months of survival has to be evaluated alongside how patients feel during those months.

Who Could Benefit First

The RASolute 302 population focused on patients with metastatic pancreatic ductal adenocarcinoma after prior treatment. In plain terms, the likely first use would be after a patient’s cancer has progressed following initial chemotherapy, assuming regulators approve the drug.

The trial included patients with a range of RAS variants, including G12 mutations, and also patients without an identified tumor RAS mutation. Primary endpoints focused on patients with RAS G12 mutations, while secondary endpoints looked at the full intent-to-treat group.

Where The Drug Stands With Regulators

Daraxonrasib is still investigational. Revolution Medicines states that it is not approved by any regulatory authority, including in the United States or Europe.

The FDA has granted Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic pancreatic ductal adenocarcinoma with G12 mutations, and the company plans to include the Phase 3 data in future regulatory submissions.

Breakthrough Therapy Designation can speed development and review when early evidence suggests a drug may offer substantial improvement over existing therapy. Approval still depends on regulatory review of the complete data package.

A Bigger Shift In Pancreatic Cancer Research

The daraxonrasib result fits into a broader wave of KRAS and RAS-directed research. MSK also reported early results in untreated pancreatic cancer patients, where daraxonrasib showed a 47% response rate among 38 treated patients, along with 71% progression-free survival at 6 months and 83% overall survival at 6 months.

Those were early-phase data, so larger randomized trials are needed before they can change first-line practice.

The larger signal is clear: pancreatic cancer research is moving away from chemotherapy alone. Molecular testing, targeted drugs, vaccines, degraders, and rational combinations are beginning to define a more precise treatment era.

Caution still belongs in the conversation. Pancreatic tumors are biologically aggressive. They develop resistance. Many patients are diagnosed late. Access to molecular testing and clinical trials remains uneven. A single positive Phase 3 trial does not solve those problems.

Why Patients Should Ask About Molecular Testing

For patients and families, one practical takeaway is the growing value of tumor profiling. KRAS status can affect clinical trial eligibility and may soon shape treatment sequencing if daraxonrasib or similar drugs gain approval.

Those conversations are time-sensitive because pancreatic cancer often moves quickly. Testing early can preserve options later.

Summary

Daraxonrasib’s Phase 3 survival result is one of the most important pancreatic cancer developments in recent years. Median survival nearly doubled against standard chemotherapy in a previously treated metastatic setting, a rare outcome in a disease with limited options.

The drug still needs regulatory review, peer-reviewed detail, and real-world experience, but the trial strengthens the case that KRAS and RAS can finally be targeted in pancreatic cancer.